Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed solid tumor for which there is no known curative therapy or therapy that is known to prolong survival with acceptable quality of life
• * Histologic requirement waived for intrinsic brain stem tumors
• No pleural effusion or ascites
• Neurological deficits from CNS tumors must have been relatively stable for at least 1 week prior to study entry
• PATIENT CHARACTERISTICS:
• Age
• 1 to 21
• Performance status
• Karnofsky 50-100% (over 10 years of age)
• Lansky 50-100% (10 years of age and under)
• Life expectancy
• At least 8 weeks
• Hematopoietic
• Absolute neutrophil count at least 1,000/mm\^3
• Platelet count at least 100,000/mm\^3 (transfusion independent)
• Hemoglobin at least 8.0 g/dL (transfusion allowed)
• Hepatic
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• ALT no greater than 2.5 times ULN
• Albumin at least 2 g/dL
• Renal
• Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min OR
• Creatinine based on age as follows:
• * No greater than 0.8 mg/dL (age 5 and under)
• * No greater than 1.0 mg/dL (age 6 to 10)
• * No greater than 1.2 mg/dL (age 11 to 15)
• * No greater than 1.5 mg/dL (age 16 and over)
• Pulmonary
• No evidence of dyspnea at rest
• No exercise intolerance
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No evidence of Approved-not yet active graft-versus-host disease
• No uncontrolled infection
• Seizure disorder allowed provided it is well-controlled with anticonvulsants
• CNS toxicity no greater than grade 1
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Recovered from prior immunotherapy
• At least 7 days since prior antineoplastic biologic therapy
• At least 6 months since prior allogeneic stem cell transplantation
• More than 1 week since prior growth factors
• No concurrent biologic therapy
• No concurrent immunotherapy
• No concurrent prophylactic growth factor support during course 1
• Chemotherapy
• No prior pemetrexed disodium
• More than 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
• No other concurrent chemotherapy
• Endocrine therapy
• Concurrent dexamethasone for CNS tumors allowed provided dose has been stable or decreasing for at least 1 week prior to study entry
• Radiotherapy
• Recovered from all prior radiotherapy
• At least 2 weeks since prior local palliative radiotherapy
• At least 6 months since prior craniospinal radiotherapy
• At least 6 months since prior radiotherapy to 50% or more of the pelvis
• At least 6 weeks since prior substantial bone marrow radiotherapy
• No concurrent radiotherapy
• Surgery
• Not specified
• Other
• No trimethoprim or sulfa within 2 days before and after study drug administration
• No concurrent nonsteroidal anti-inflammatory agents (e.g., ibuprofen and aspirin)
• No other concurrent anticancer or investigational agents